Bionano Genomics, Inc.
For the period ended Dec 31, 2025. Filed Mar 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 23, 2026
BNGO$1.16+0.9%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Revenue: | ||
| Product revenue | $26,743,000 | $27,008,000 |
| Service and other revenue | 1,765,000 | 3,768,000 |
| Total revenue | 28,508,000 | 30,776,000 |
| Cost of revenue: | ||
| Cost of product revenue | 14,429,000 | 28,449,000 |
| Cost of service and other revenue | 894,000 | 1,947,000 |
| Total cost of revenue | 15,323,000 | 30,396,000 |
| Operating expenses: | ||
| Research and development | 11,374,000 | 24,803,000 |
| Selling, general and administrative | 35,150,000 | 51,855,000 |
| Intangible assets and other long-lived assets impairment | — | 19,683,000 |
| Restructuring costs | — | 8,022,000 |
| Total operating expenses | 46,524,000 | 104,363,000 |
| Loss from operations | (33,339,000) | (103,983,000) |
| Other income (expense): | ||
| Interest income | 1,111,000 | 2,101,000 |
| Other income (expense) | 5,900,000 | (10,102,000) |
| Total other income (expense) | 7,011,000 | (8,001,000) |
| Loss before income taxes | (26,328,000) | (111,984,000) |
| Provision for income taxes | (67,000) | (33,000) |
| Net loss | $(26,395,000) | $(112,017,000) |
| Net loss per share, basic and diluted | $(4.85) | $(88.13) |
| Weighted-average common shares outstanding, basic and diluted | 5,445,000 | 1,271,000 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.